S&P 500   3,140.06 (+0.24%)
DOW   27,891.71 (+0.04%)
QQQ   204.97 (+0.52%)
AAPL   270.70 (+0.83%)
FB   202.45 (+0.78%)
MSFT   151.67 (+0.36%)
GOOGL   1,344.52 (+0.12%)
AMZN   1,746.83 (+0.44%)
CGC   20.27 (+0.90%)
NVDA   216.85 (+1.34%)
MU   49.19 (+3.65%)
BABA   204.16 (+1.85%)
GE   10.99 (-0.18%)
T   38.12 (+0.13%)
F   9.13 (+0.55%)
BAC   33.71 (+0.54%)
GILD   67.62 (+0.80%)
DIS   147.54 (+0.99%)
S&P 500   3,140.06 (+0.24%)
DOW   27,891.71 (+0.04%)
QQQ   204.97 (+0.52%)
AAPL   270.70 (+0.83%)
FB   202.45 (+0.78%)
MSFT   151.67 (+0.36%)
GOOGL   1,344.52 (+0.12%)
AMZN   1,746.83 (+0.44%)
CGC   20.27 (+0.90%)
NVDA   216.85 (+1.34%)
MU   49.19 (+3.65%)
BABA   204.16 (+1.85%)
GE   10.99 (-0.18%)
T   38.12 (+0.13%)
F   9.13 (+0.55%)
BAC   33.71 (+0.54%)
GILD   67.62 (+0.80%)
DIS   147.54 (+0.99%)
S&P 500   3,140.06 (+0.24%)
DOW   27,891.71 (+0.04%)
QQQ   204.97 (+0.52%)
AAPL   270.70 (+0.83%)
FB   202.45 (+0.78%)
MSFT   151.67 (+0.36%)
GOOGL   1,344.52 (+0.12%)
AMZN   1,746.83 (+0.44%)
CGC   20.27 (+0.90%)
NVDA   216.85 (+1.34%)
MU   49.19 (+3.65%)
BABA   204.16 (+1.85%)
GE   10.99 (-0.18%)
T   38.12 (+0.13%)
F   9.13 (+0.55%)
BAC   33.71 (+0.54%)
GILD   67.62 (+0.80%)
DIS   147.54 (+0.99%)
S&P 500   3,140.06 (+0.24%)
DOW   27,891.71 (+0.04%)
QQQ   204.97 (+0.52%)
AAPL   270.70 (+0.83%)
FB   202.45 (+0.78%)
MSFT   151.67 (+0.36%)
GOOGL   1,344.52 (+0.12%)
AMZN   1,746.83 (+0.44%)
CGC   20.27 (+0.90%)
NVDA   216.85 (+1.34%)
MU   49.19 (+3.65%)
BABA   204.16 (+1.85%)
GE   10.99 (-0.18%)
T   38.12 (+0.13%)
F   9.13 (+0.55%)
BAC   33.71 (+0.54%)
GILD   67.62 (+0.80%)
DIS   147.54 (+0.99%)
Log in

NASDAQ:ECOR - electroCore Stock Price, Forecast & News

$1.55
-0.02 (-1.27 %)
(As of 12/11/2019 03:49 PM ET)
Today's Range
$1.46
Now: $1.55
$1.57
50-Day Range
$1.39
MA: $1.62
$1.99
52-Week Range
$1.23
Now: $1.55
$10.24
Volume90,625 shs
Average Volume191,602 shs
Market Capitalization$45.75 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41
electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ECOR
CUSIPN/A
CIKN/A
Phone973-290-0097

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$990,000.00
Book Value$2.33 per share

Profitability

Net Income$-55,820,000.00

Miscellaneous

Employees91
Market Cap$45.75 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive ECOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ECOR and its competitors with MarketBeat's FREE daily newsletter.


electroCore (NASDAQ:ECOR) Frequently Asked Questions

What is electroCore's stock symbol?

electroCore trades on the NASDAQ under the ticker symbol "ECOR."

How were electroCore's earnings last quarter?

electroCore, Inc. (NASDAQ:ECOR) released its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.05. The firm earned $0.68 million during the quarter. View electroCore's Earnings History.

When is electroCore's next earnings date?

electroCore is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for electroCore.

What price target have analysts set for ECOR?

5 brokerages have issued twelve-month target prices for electroCore's stock. Their forecasts range from $2.00 to $11.00. On average, they anticipate electroCore's share price to reach $8.00 in the next year. This suggests a possible upside of 422.9% from the stock's current price. View Analyst Price Targets for electroCore.

What is the consensus analysts' recommendation for electroCore?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for electroCore in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for electroCore.

What are Wall Street analysts saying about electroCore stock?

Here are some recent quotes from research analysts about electroCore stock:
  • 1. According to Zacks Investment Research, "Electrocore, LLC operates as a bio-electronic medicine company. It reseraches and develops therapeutic technologies based in neurology and rheumatology. Electrocore, LLC is based in NJ, United States. " (11/27/2019)
  • 2. Evercore ISI analysts commented, "We think the TETRAS-ADL endpoint was most interesting (see image at bottom) … and this will be the primary endpoint in future clinical trials." (8/13/2019)

Has electroCore been receiving favorable news coverage?

Media headlines about ECOR stock have trended neutral on Wednesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. electroCore earned a news impact score of 0.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for electroCore.

Are investors shorting electroCore?

electroCore saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,600,000 shares, an increase of 11.1% from the September 30th total of 1,440,000 shares. Based on an average daily volume of 223,700 shares, the days-to-cover ratio is presently 7.2 days. Approximately 7.3% of the company's shares are short sold. View electroCore's Current Options Chain.

Who are some of electroCore's key competitors?

What other stocks do shareholders of electroCore own?

Based on aggregate information from My MarketBeat watchlists, some companies that other electroCore investors own include Crispr Therapeutics (CRSP), Canopy Growth (CGC), Allena Pharmaceuticals (ALNA), Mesoblast (MESO), Opko Health (OPK), Arcadia Biosciences (RKDA), NIO (NIO), Protalix Biotherapeutics (PLX), Akari Therapeutics (AKTX) and Amyris (AMRS).

Who are electroCore's key executives?

electroCore's management team includes the folowing people:
  • Mr. Francis R. Amato, CEO & Director (Age 55)
  • Mr. Joseph P. Errico, Co-Founder, Chief Science & Strategy Officer, Principal Investor & Director (Age 50)
  • Mr. Glenn S. Vraniak, Exec. Officer (Age 56)
  • Dr. Peter S. Staats, Sr. Exec. Advisor of Medical & Gov. Affairs (Age 55)
  • Mr. Steven M. Mendez, Founder & CTO (Age 58)

When did electroCore IPO?

(ECOR) raised $64 million in an IPO on Friday, June 22nd 2018. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Evercore ISI and JMP Securities acted as the underwriters for the IPO and BTIG was co-manager.

Who are electroCore's major shareholders?

electroCore's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (0.70%), Bfsg LLC (0.24%), Brighton Jones LLC (0.18%) and Valeo Financial Advisors LLC (0.15%). Company insiders that own electroCore stock include Brian M Posner, Carrie Smith Cox, Francis R Amato, Global Health Innovation Merck, James L L Tullis, Joseph P Errico, Peter S Staats and Thomas J Errico. View Institutional Ownership Trends for electroCore.

Which major investors are buying electroCore stock?

ECOR stock was bought by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC, State Street Corp, Bfsg LLC and Brighton Jones LLC. Company insiders that have bought electroCore stock in the last two years include Brian M Posner, Carrie Smith Cox, Francis R Amato, Global Health Innovation Merck, James L L Tullis, Peter S Staats and Thomas J Errico. View Insider Buying and Selling for electroCore.

How do I buy shares of electroCore?

Shares of ECOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is electroCore's stock price today?

One share of ECOR stock can currently be purchased for approximately $1.53.

How big of a company is electroCore?

electroCore has a market capitalization of $45.16 million and generates $990,000.00 in revenue each year. The company earns $-55,820,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. electroCore employs 91 workers across the globe.View Additional Information About electroCore.

What is electroCore's official website?

The official website for electroCore is http://www.electrocore.com/.

How can I contact electroCore?

electroCore's mailing address is 150 ALLEN ROAD SUITE 201, BASKING RIDGE NJ, 07920. The company can be reached via phone at 973-290-0097 or via email at [email protected]


MarketBeat Community Rating for electroCore (NASDAQ ECOR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  286
MarketBeat's community ratings are surveys of what our community members think about electroCore and other stocks. Vote "Outperform" if you believe ECOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel